Johnson & Johnson pays $50M to resolve its ugly divorce with Emergent BioSolutions

09 Jul 2024
·
Deals
www.fiercepharma.com
VaccinePatent InfringementmRNA
Johnson & Johnson pays $50M to resolve its ugly divorce with Emergent BioSolutions
Preview
Source: FiercePharma
Emergent BioSolutions will receive $50 million from Johnson & Johnson to resolve a contract dispute over production of COVID-19 vaccinesCOVID-19 vaccines.
Johnson & Johnson will pay Emergent BioSolutions $50 million to settle a two-year contract squabble and bring closure to an ill-fated, government-arranged partnership between the biopharma giant and the contract manufacturer to produce COVID-19 vaccinesCOVID-19 vaccines.
According to a filing with the Securities and Exchange Commission (SEC), J&J has agreed to pay Emergent $50 million by the end of this month to resolve the CDMO’s claims of breach of contract.
In 2022, J&J terminated a five-year deal that called for Emergent to produce drug substance for J&J’s COVID-19 vaccineCOVID-19 vaccine. The Maryland manufacturer responded in an SEC filing that J&J was on the hook for $420 million for bailing on the agreement. Two months later, J&J filed its own breach of contract complaint against Emergent and asked for an arbitration.
The contract battle began after Emergent made high-profile errors at its sprawling Bayside plant in Baltimore where it was producing COVID vaccines for AstraZeneca and J&J. The mistakes caused millions of contaminated vaccine doses to be discarded and led the FDA to hand control of the plant over to J&J in April 2021.
Meanwhile, J&J was struggling with rare blood clotting issues with its COVID vaccine, which led the FDA to limit its use in May 2022.
In response to the settlement agreement Monday, Emergent’s share price rose by 2%. Since the start of the year, its shares are up 214% as the company has shown signs of recovering from its COVID debacle.
In May, new CEO Joe Papa announced a restructuring that includes the closure of two of its plants in Maryland, including the Baltimore Bayside facility, and a staff reduction by 300 roles.
Three weeks ago, the company also announced the sale of its smaller, fill-finish Camden facility in Baltimore to Bora Pharmaceuticals for $30 million.
Last week, Emergent revealed that it had signed a U.S. government contract for more than $250 million to produce vaccines to be stockpiled for use against anthrax, botulism and smallpox. The company will produce the shots from its sites in Winnipeg, Canada, and Lansing, Michigan.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.